A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers

The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.

Inclusion Criteria

• Is an adult healthy volunteer
• Has a body mass index ≥18 kg/m^2 and ≤28 kg/m^2

Exclusion Criteria

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN)
• Has known human immunodeficiency virus infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
• Has an estimated glomerular filtration rate (eGFR) of <90 mL/min/1.73m^2 at screening

Note: other protocol defined inclusion / exclusion criteria apply